Literature DB >> 18201781

Changing trends (1986-2003) in the use of lipid lowering medication in patients hospitalized with acute myocardial infarction: a community-based perspective.

Jorge Yarzebski1, Edgard Granillo, Frederick A Spencer, Darleen Lessard, Jerry H Gurwitz, Joel M Gore, Robert J Goldberg.   

Abstract

OBJECTIVES: The objectives of this community-wide observational study were to describe nearly two decade long (1986-2003) trends in the use of lipid lowering therapy in patients hospitalized with acute myocardial infarction (AMI) and clinical and demographic factors associated with underutilization of this treatment regimen.
METHODS: A total of 9429 greater Worcester (MA) residents hospitalized with confirmed AMI at all metropolitan Worcester medical centers in 10 annual periods between 1986 and 2003 comprised the study population. Hospital medical records were reviewed to ascertain the prescribing of lipid lowering agents during hospitalization for AMI.
RESULTS: The mean age of the study sample was 70 years, 58% were men, and the average total and LDL serum cholesterol levels were 203 and 114 mg/dL, respectively. There was a marked increase in the use of lipid lowering therapy in greater Worcester residents hospitalized with AMI between 1986 (<1%) and 2003 (76%). Increasing use of lipid lowering medication was observed both with regards to the maintenance of this therapy in patients who were already on this treatment regimen and in the new initiation of lipid lowering medication in patients who had not been previously treated with this therapy. Several patient demographic and clinical factors, including advanced age and an initial AMI, were associated with the failure to be prescribed lipid lowering therapy during hospitalization for AMI.
CONCLUSIONS: The results of this study suggest encouraging increases over time in the use of lipid lowering therapy in patients hospitalized with AMI. Despite these encouraging trends, several high-risk patient groups remain suboptimally treated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201781      PMCID: PMC4569868          DOI: 10.1016/j.ijcard.2007.10.055

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  30 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.

Authors:  S R Majumdar; J H Gurwitz; S B Soumerai
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

3.  Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction.

Authors:  Frederick A Spencer; Darleen Lessard; Jorge Yarzebski; Joel M Gore; Robert J Goldberg
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

4.  Trends in plasma cholesterol levels in the atherosclerosis risk in communities (ARIC) study.

Authors:  M Szklo; L E Chambless; A R Folsom; A Gotto; F J Nieto; W Patsch; T Shimakawa; P Sorlie; L Wijnberg
Journal:  Prev Med       Date:  2000-03       Impact factor: 4.018

5.  Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.

Authors:  Frank M Sacks; Andrew M Tonkin; Timothy Craven; Marc A Pfeffer; James Shepherd; Anthony Keech; Curt D Furberg; Eugene Braunwald
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

6.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.

Authors:  W J Rogers; J G Canto; C T Lambrew; A J Tiefenbrunn; B Kinkaid; D A Shoultz; P D Frederick; N Every
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

7.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease.

Authors:  P McBride; H G Schrott; M B Plane; G Underbakke; R L Brown
Journal:  Arch Intern Med       Date:  1998-06-08

10.  Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study.

Authors:  R J Goldberg; J M Gore; J S Alpert; J E Dalen
Journal:  JAMA       Date:  1986 May 23-30       Impact factor: 56.272

View more
  2 in total

1.  Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.

Authors:  Ute Amann; Inge Kirchberger; Margit Heier; Hildegard Golüke; Wolfgang von Scheidt; Bernhard Kuch; Annette Peters; Christa Meisinger
Journal:  Clin Res Cardiol       Date:  2014-03-07       Impact factor: 5.460

2.  Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.

Authors:  Andrea V Margulis; Niteesh K Choudhry; Colin R Dormuth; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-04-28       Impact factor: 2.890

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.